Predictors of serological cure and Serofast State after treatment in HIV-negative persons with early syphilis
- PMID: 21998287
- PMCID: PMC3205200
- DOI: 10.1093/cid/cir671
Predictors of serological cure and Serofast State after treatment in HIV-negative persons with early syphilis
Abstract
Background: Syphilis management requires serological monitoring after therapy. We compared factors associated with serological response after treatment of early (ie, primary, secondary, or early latent) syphilis.
Methods: We performed secondary analyses of data from a prospective, randomized syphilis trial conducted in the United States and Madagascar. Human immunodeficiency virus (HIV)-negative participants aged ≥ 18 years with early syphilis were enrolled from 2000-2009. Serological testing was performed at baseline and at 3 and 6 months after treatment. At 6 months, serological cure was defined as a negative rapid plasma reagin (RPR) test or a ≥4-fold decreased titer, and serofast status was defined as a ≤ 2-fold decreased titer or persistent titers that did not meet criteria for treatment failure.
Results: Data were available from 465 participants, of whom 369 (79%) achieved serological cure and 96 (21%) were serofast. In bivariate analysis, serological cure was associated with younger age, fewer sex partners, higher baseline RPR titers, and earlier syphilis stage (P ≤ .008). There was a less significant association with Jarisch-Herxheimer reaction after treatment (P = .08). Multivariate analysis revealed interactions between log-transformed baseline titer with syphilis stage, in which the likelihood of cure was associated with increased titers among participants with primary syphilis (adjusted odds ratio [AOR] for 1 unit change in log(2) titer, 1.83; 95% confidence interval [CI], 1.25-2.70), secondary syphilis (AOR, 3.15; 95% CI, 2.14-4.65), and early latent syphilis (AOR, 1.86; 95% CI, 1.44-2.40).
Conclusions: Serological cure at 6 months after early syphilis treatment is associated with age, number of sex partners, Jarisch-Herxheimer reaction, and an interaction between syphilis stage and baseline RPR titer.
Figures
Comment in
-
Predictors of serological cure after treatment of early syphilis.Clin Infect Dis. 2012 Apr;54(7):1037; author reply 1037-8. doi: 10.1093/cid/cir1010. Epub 2012 Feb 8. Clin Infect Dis. 2012. PMID: 22323565 No abstract available.
References
-
- Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. Morb Mort Wkly Rep. 2010;58(RR–12):26–34.
-
- Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med. 1997;337:307–14. - PubMed
-
- Hook EW, Behets F, van Damm K, et al. A phase III equivalence trial of azithromycin vs benzathine penicillin for treatment of early syphilis. J Infect Dis. 2010;201:1729–35. - PubMed
-
- Hook EW, 3rd, Martin DH, Stephens J, Smith BS, Smith K. A randomized, comparative pilot study of azithromycin versus benzathine penicillin G for treatment of early syphilis. Sex Transm Dis. 2002;29:486–90. - PubMed
